Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 272

The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.

Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition

Open access
Ngo, Bryan, Kim, Eugenie, Osorio-Vasquez, Victoria, Doll, Sophia, Bustraan, Sophia, Liang, Roger J., Luengo, Alba, Davidson, Shawn M., Ali, Ahmed, Ferraro, Gino B., Fischer, Grant M., Eskandari, Roozbeh, Kang, Diane S., Ni, Jing, Plasger, Ariana, Rajasekhar, Vinagolu K., Kastenhuber, Edward R., Bacha, Sarah, Sriram, Roshan K., Stein, Benjamin D., Bakhoum, Samuel F., Snuderl, Matija, Cotzia, Paolo, Healey, John H., Mainolfi, Nello, Suri, Vipin, Friedman, Adam, Manfredi, Mark, Sabatini, David M., Jones, Drew R., Yu, Min, Zhao, Jean J., Jain, Rakesh K., Keshari, Kayvan R., Davies, Michael A., Vander Heiden, Matthew G., Hernando, Eva, Mann, Matthias, Cantley, Lewis C., Pacold, Michael E. · 2020 · Cancer Discovery

Published version of a preprint

Abstract

A hallmark of metastasis is the adaptation of tumor cells to new environments. Metabolic constraints imposed by the serine and glycine–limited brain environment restrict metastatic tumor growth. How brain metastases overcome these growth-prohibitive conditions is poorly understood. Here, we demonstrate that 3-phosphoglycerate dehydrogenase (PHGDH), which catalyzes the rate-limiting step of glucose-derived serine synthesis, is a major determinant of brain metastasis in multiple human cancer types and preclinical models. Enhanced serine synthesis proved important for nucleotide production and cell proliferation in highly aggressive brain metastatic cells. In vivo, genetic suppression and pharmacologic inhibition of PHGDH attenuated brain metastasis, but not extracranial tumor growth, and improved overall survival in mice. These results reveal that extracellular amino acid availability determines serine synthesis pathway dependence, and suggest that PHGDH inhibitors may be useful in the treatment of brain metastasis. Significance: Using proteomics, metabolomics, and multiple brain metastasis models, we demonstrate that the nutrient-limited environment of the brain potentiates brain metastasis susceptibility to serine synthesis inhibition. These findings underscore the importance of studying cancer metabolism in physiologically relevant contexts, and provide a rationale for using PHGDH inhibitors to treat brain metastasis. This article is highlighted in the In This Issue feature, p. 1241

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-19-1228

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 2

  1. Jones, 2006, Reference data for cerebrospinal fluid and the utility of amino acid measurement for the diagnosis of inborn errors of metabolism, Ann Clin Biochem, 43, 63, 10.1258/000456306775141759 · doi:10.1258/000456306775141759
  2. Tee, 2016, Sampling hyperpolarized molecules utilizing a 1 Tesla permanent magnetic field, Sci Rep, 6, 32846, 10.1038/srep32846 · doi:10.1038/srep32846

Cited by

See all 272

Metadata

Authors
Ngo, B., Kim, E., Osorio-Vasquez, V., Doll, S., Bustraan, S., Liang, R. J., Luengo, A., Davidson, S. M., Ali, A., Ferraro, G. B., Fischer, G. M., Eskandari, R., Kang, D. S., Ni, J., Plasger, A., Rajasekhar, V. K., Kastenhuber, E. R., Bacha, S., Sriram, R. K., Stein, B. D., Bakhoum, S. F., Snuderl, M., Cotzia, P., Healey, J. H., Mainolfi, N., Suri, V., Friedman, A., Manfredi, M., Sabatini, D. M., Jones, D. R., Yu, M., Zhao, J. J., Jain, R. K., Keshari, K. R., Davies, M. A., Vander Heiden, M. G., Hernando, E., Mann, M., Cantley, L. C., & Pacold, M. E.
Venue
Cancer Discovery
Published
2020-09-01
Volume
10
Issue
9
Pages
1352-1373
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W3035766511
Cited by
272
References
92
FWCI
9.99
Type
journal article
Language
en
Open access
green
Funders
  • HHS | National Institutes of Health (F99CA234950, DP5OD026395, R03 DA034602-01A1, R01 CA129105, R01 CA103866, R37 AI047389, R01 CA126642, R01 CA085140, R01 CA115767, R01 CA098706, R01 CA208205, U01 CA224173, R35 CA197743, R21CA198028, R01CA168653, K22 CA175228-01A1, DP2 CA206653, R35CA197588, F31 CA250364, T32GM007287, R35 CA210057, P50 CA168504, R01CA237466, R01CA252037, R21CA212958)
  • National Science Foundation (T32GM007287)
  • U.S. Department of Defense (BC151244, W81XWH-10-1-0016, W81XWH-18-1-0491)
  • Burroughs Wellcome Fund
  • Howard Hughes Medical Institute
  • HHS | NIH | National Cancer Institute (P01 CA080124, K22CA212059, P30-CA008748, R37 AI047389, R01 CA121118-06A1, 2T32CA009666-21, R01CA2022027, P01CA206980, 1P50CA225450, U54 CA210184, 5P30CA016087)
  • Lustgarten Foundation
  • Pew Charitable Trusts
  • Breast Cancer Research Foundation
  • Mary Kay Foundation (017-32)
  • V Foundation for Cancer Research (V2017-004)
  • Shifrin-Myers Breast Cancer Discovery Fund
  • HHS | NIH | National Center for Advancing Translational Sciences (TL1TR000369, UL1TR000371)
  • Tow Foundation
  • UT | University of Texas MD Anderson Cancer Center
  • Starr Foundation
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  • AIM at Melanoma
  • Cancer Prevention and Research Institute of Texas (RP170401, RP160183)
  • Max Planck Society for the Advancement of Science
  • EC | Horizon 2020 (686547)
  • European Commission (GA ERC-202120Syg_318987)
  • Novo Nordisk Foundation for the Clinical Proteomics group (NNF15CC0001)
  • Melanoma Research Alliance (688365)
  • American Association for Cancer Research (SU2C-AACR-IRG-09-16)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.